CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

A new study published in Psychological Medicine sheds light on how specific depression symptoms are related to decisions ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...